Source: ALL

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 Biomarker BEFREE Herein, we review the key molecular effects associated with NOS2 in ovarian and prostate cancer. 28326819

2017
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 GeneticVariation BEFREE Our results suggest that NOS2 polymorphisms may influence the risk of aggressive prostate cancer and that these polymorphisms could have an impact on disease pathogenesis, possibly by affecting intracellular nitric oxide levels. 28162285

2015
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 Biomarker BEFREE Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors. 22859398

2012
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 Biomarker BEFREE We consider that these findings provide a basis for the development of systemically delivered PSMA/iNOS or hOC/iNOS targeting early stage and advanced prostate cancer. 20821746

2010
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 AlteredExpression BEFREE Nitric oxide synthase 2 (NOS2) inducible expression is closely correlated with prostatic disease, including prostate cancer and BPH. 20562898

2010
Entrez Id: 4843
Gene Symbol: NOS2
NOS2
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.060 GeneticVariation BEFREE The NOS2A IVS16 + 88 GT/TT was associated with increased prostate cancer risk (odds ratio = 1.24, 95% confidence interval = 1.00-1.54), whereas the IVS20 + 524 AG/GG was associated with decreased risk (0.77, 0.66-0.90). 19168583

2009